<?xml version='1.0' encoding='utf-8'?>
<document id="31528502"><sentence text="Cabozantinib and apixaban: an hitherto unreported interaction."><entity charOffset="0-12" id="DDI-PubMed.31528502.s1.e0" text="Cabozantinib" /><entity charOffset="17-25" id="DDI-PubMed.31528502.s1.e1" text="apixaban" /><pair ddi="false" e1="DDI-PubMed.31528502.s1.e0" e2="DDI-PubMed.31528502.s1.e0" /><pair ddi="false" e1="DDI-PubMed.31528502.s1.e0" e2="DDI-PubMed.31528502.s1.e1" /></sentence><sentence text="The use of direct oral anticoagulant in cancer patients is an emerging issue, which seems to be an alternative to low molecular weight heparin" /><sentence text=" Every year several new drugs are approved as anticancer treatment with possible drug-drug interaction with other drugs such as oral anticoagulant" /><sentence text=" We describe, for the first time, a case of neutropenia and thrombocytopenia in a patient in treatment with cabozantinib, a novel anticancer treatment used in metastatic renal cell carcinoma, and apixaban with promptly resumption of the toxicity after the interruption of cabozantinib"><entity charOffset="108-120" id="DDI-PubMed.31528502.s4.e0" text="cabozantinib" /><entity charOffset="272-284" id="DDI-PubMed.31528502.s4.e1" text="cabozantinib" /><pair ddi="false" e1="DDI-PubMed.31528502.s4.e0" e2="DDI-PubMed.31528502.s4.e0" /><pair ddi="false" e1="DDI-PubMed.31528502.s4.e0" e2="DDI-PubMed.31528502.s4.e1" /></sentence><sentence text=" This case suggest a possible interaction between these two pharmaceutical agents, which merit caution considering the spreading of the two drugs" /><sentence text="" /></document>